Amedica, a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, announced that it will host a conference call and live webcast to present the 24-month clinical results from a blinded, randomized clinical trial (Cascade) that compared spinal fusion between its composite silicon nitride fusion devices with a central, cancellous ceramic core, to the industry standard of PEEK spacers filled with bone autograft.
Principal investigator Mark P. Arts, M.D., Ph.D., Neurosurgeon from the Medical Center Haaglanden, The Hague, Netherlands will present the data and Dr. Sonny Bal, Chairman and CEO of Amedica Corporation will discuss its impact on the business. Details related to this call are as follows:
Date: Monday, March 7, 2016
Times: 2:00 p.m. Eastern Time
Conference ID: 55371714
Dial-in: Toll-free (855) 455-6055
International (484) 756-4308
Webcast: amedica.com
For those who are not available to listen to the live webcast, the call will be archived on the investor relations section of the Amedica website under Events & Presentations.
